Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer

NCT06068543 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.

NCT NCT06068543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06068543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer
Lead sponsor
University of Rochester
Phase
Phase 2
Overall status
Suspended
Start date
October 25, 2024
Completion date
December 31, 2030
Enrollment
118 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

frailty, inflammation